Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
>#vLOCK|ctKLOCK|#v%$sdf

J&J Earnings: Raising Our Fair Value on New Launches, but Long-Term Guidance Looks Optimistic

Johnson & Johnson reported 9.9% sales growth and adjusted earnings per share down 2.5% in the first quarter. Management raised its 2026 growth guidance midpoints by 30 basis points to 7% on the top line and by 20 basis points to 5.7% for adjusted EPS. Shares were up 1% during April 14 trading.

Sponsor Center